CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy?

Shares of CureVac (NASDAQ:CVAC) gapped up before the market opened on Tuesday . The stock had previously closed at $2.79, but opened at $2.95. CureVac shares last traded at $2.88, with a volume of 171,953 shares changing hands.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a report on Monday, September 16th.

CureVac Stock Performance

The company has a current ratio of 2.29, a quick ratio of 2.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $615.67 million, a P/E ratio of 5.15, a P/E/G ratio of 2.04 and a beta of 2.61. The company’s 50-day moving average is $2.93 and its two-hundred day moving average is $3.26.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a return on equity of 25.55% and a net margin of 20.72%. The business had revenue of $15.55 million for the quarter, compared to analyst estimates of $10.07 million. As a group, sell-side analysts anticipate that CureVac will post 0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently modified their holdings of CVAC. Point72 Asset Management L.P. bought a new stake in shares of CureVac in the 2nd quarter worth approximately $8,237,000. Platinum Investment Management Ltd. boosted its stake in shares of CureVac by 25.9% during the 1st quarter. Platinum Investment Management Ltd. now owns 626,684 shares of the company’s stock worth $1,899,000 after acquiring an additional 128,778 shares in the last quarter. Tidal Investments LLC acquired a new position in shares of CureVac in the 1st quarter worth $175,000. Vanguard Personalized Indexing Management LLC raised its position in shares of CureVac by 99.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after purchasing an additional 21,999 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after purchasing an additional 16,792 shares during the period. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.